Different rates of CD4+ and CD8+ T-cell proliferation in interleukin-2 - Treated human immunodeficiency virus-positive subjects

Cytometry

Volumn 44, Issue 4, 2001, Pages 233-237

  Caggiari, L ^a   Zanussi, S ^a   Crepaldi, C ^a   Bortolin, M T ^a   Caffau, C ^a   D'Andrea, M ^a   De Paoli, P ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

CD4; CD8; HIV; IL 2 therapy; Ki67

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; KI 67 ANTIGEN; RECOMBINANT INTERLEUKIN 2; INTERLEUKIN 2;

ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FLOW CYTOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSTIMULATION; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; APOPTOSIS; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIVISION; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM;

HUMAN IMMUNODEFICIENCY VIRUS;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; APOPTOSIS; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIVISION; DRUG THERAPY, COMBINATION; FLOW CYTOMETRY; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; KI-67 ANTIGEN;

EID: 0035880444     PISSN: 01964763     EISSN: None     Source Type: Journal    
DOI: 10.1002/cyto.1132     Document Type: Article

References (26)

1. Recovery of the immune system with antiretroviral therapy
2. Persistent alterations in T-cell repertoire, cytokine and chemokine receptor gene expression after 1 year of HAART
3. Increases in CD4 T lymphocytes with intermittent courses of IL-2 in patients with HIV infection
4. Subcutaneous administration of IL-2 in HIV type 1-infected persons
5. Effects of subcutaneous IL-2 therapy on CD4 subsets and in vitro cytokine production in HIV+ patients
6. Immunological changes in peripheral blood and in lymphoid tissue after treatment of HIV-infected subjects with HAART or HAART+IL-2
7. Reduction of the HIV-infected T cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs
8. Efficacy of low-dose subcutaneous IL-2 to treat advanced HIV type 1 in persons with <250/mmc CD4 T cells and undetectable plasma virus load
9. Concomitant therapy with s.c. IL-2 and zidovudine plus didanosine in patients with early stage HIV infection
10. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
11. Effect of cryopreservation on measurement of CMV-specific cellular immune response in HIV-infected patients
12. Effects of IL-2 on the proliferation and differentiation of CD4/CD25 positive and CD4/CD25 negative cells in HIV patients
13. Turnover of CD4+ and CD8+ T lymphocytes in HIV-1 infection as measured by Ki67 antigen
14. T cell division in HIV-1 infection is mainly due to immune activation: A longitudinal analysis in patients before and during HAART
15. Statistics and causal inference
16. Patient heterogeneity and the need for randomized clinical trials
17. Randomization, statistics and causal inference
18. The dynamics of T-lymphocyte turnover in AIDS
19. Measurement of T-cell kinetics: Recent methodologic advances
20. Pooled analysis of 3 randomized, controlled trials of IL-2 therapy in adult HIV disease
21. The immunological effects of IL-2 therapy in HIV-positive subjects
22. Immunomodulatory properties and toxicity of IL-2 in patients with cancer
23. Phase I trial of escalating doses of IL1-beta in comparison to a fixed dose of IL-2
24. Immunological changes in peripheral blood mononuclear cells in metastatic renal cell carcinoma after low doses of sc immunotherapy with IFN-alfa and IL-2
25. Immunopathogenic mechanisms in HIV infection
26. Effects of therapy with HAART and IL-2 on CD4+ and CD8+ lymphocyte apoptosis in HIV+ patients